These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 17548567

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Recent advances in pathogenesis and therapy of multiple sclerosis].
    Linker RA, Stadelmann C, Diem R, Bähr M, Brück W, Gold R.
    Fortschr Neurol Psychiatr; 2005 Dec; 73(12):715-27. PubMed ID: 16355314
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
    Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T.
    Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pathogenesis of axonal and neuronal damage in multiple sclerosis.
    Dutta R, Trapp BD.
    Neurology; 2007 May 29; 68(22 Suppl 3):S22-31; discussion S43-54. PubMed ID: 17548565
    [Abstract] [Full Text] [Related]

  • 8. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct 29; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
    Lopez-Diego RS, Weiner HL.
    Nat Rev Drug Discov; 2008 Nov 29; 7(11):909-25. PubMed ID: 18974749
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New directions in MS therapeutics: vehicles of hope.
    Fox RJ, Ransohoff RM.
    Trends Immunol; 2004 Dec 29; 25(12):632-6. PubMed ID: 15530830
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis.
    Waxman SG.
    Trends Mol Med; 2006 May 29; 12(5):192-5. PubMed ID: 16574486
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Neuroprotection and repair.
    Palace J.
    J Neurol Sci; 2008 Feb 15; 265(1-2):21-5. PubMed ID: 17964604
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotection in multiple sclerosis.
    Karussis D, Grigoriadis S, Polyzoidou E, Grigoriadis N, Slavin S, Abramsky O.
    Clin Neurol Neurosurg; 2006 Mar 15; 108(3):250-4. PubMed ID: 16413962
    [Abstract] [Full Text] [Related]

  • 18. Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?
    Khan O.
    Neurology; 2007 May 29; 68(22 Suppl 3):S64-71; discussion S91-6. PubMed ID: 17548572
    [Abstract] [Full Text] [Related]

  • 19. Emerging therapeutic targets in multiple sclerosis.
    Fontoura P, Steinman L, Miller A.
    Curr Opin Neurol; 2006 Jun 29; 19(3):260-6. PubMed ID: 16702832
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.